← Back to Search

Tech-Based Caregiver Support for Alzheimer's Disease (TACAD Trial)

N/A

Waitlist Available

Led By Eun-Ok Im, PhD, MPH

Research Sponsored by University of Texas at Austin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 months post intervention, 3 months post intervention

Awards & highlights

TACAD Trial Summary

This trial will assess a technology-based program to help Asian American midlife caregivers of Alzheimer's patients improve their health and care for their loved ones.

Who is the study for?

This trial is for Asian American women, aged 40-65, who are Chinese or Korean and care for family members with early to middle-stage Alzheimer's. They must read/write English, Mandarin, or Korean, live in the U.S., have internet access, and provide at least 4 hours of daily unpaid care without plans for institutionalizing the patient within six months.Check my eligibility

What is being tested?

The study tests a program called TACAD against using the Alzheimer's Association website. It aims to see if TACAD can better improve health outcomes for these caregivers and their patients living with Alzheimer's disease by providing tailored information and coaching/support.See study design

What are the potential side effects?

Since this trial involves an informational program rather than medication, traditional side effects aren't expected. Participants may experience emotional distress or fatigue from engaging with caregiving content.

TACAD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 months post intervention, 3 months post intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 months post intervention, 3 months post intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 months post intervention, 3 months post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Acculturation Stress Scale (ASS) score from baseline

Change in EQ-5D-5L scale score from baseline

Change in Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score from baseline

+8 more

Secondary outcome measures

Change in Caregiver Activity Survey score from baseline

Change in Caregiver Assessment of Behavioral Skill Scale score from baseline

Change in Pearlin Mastery, Loss, and Competence Scale score from baseline

+1 more

TACAD Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment2 Interventions

Patient will use TACAD and the Alzheimer's Association Website

Group II: Active Control GroupActive Control1 Intervention

Patient will use only the Alzheimer's Association Website

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor

356 Previous Clinical Trials

81,419 Total Patients Enrolled

Emory UniversityLead Sponsor

1,642 Previous Clinical Trials

2,563,946 Total Patients Enrolled

Eun-Ok Im, PhD, MPHPrincipal InvestigatorEmory University

2 Previous Clinical Trials

499 Total Patients Enrolled

Media Library

TACAD Clinical Trial Eligibility Overview. Trial Name: NCT05615233 — N/A

Alzheimer's Disease Research Study Groups: Intervention Group, Active Control Group

Alzheimer's Disease Clinical Trial 2023: TACAD Highlights & Side Effects. Trial Name: NCT05615233 — N/A

TACAD 2023 Treatment Timeline for Medical Study. Trial Name: NCT05615233 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are senior citizens over 65 years old barred from participating in this clinical research?

"As specified by this trial's requirements, the minimum and maximum age of enrolment is 40 and 65 years old respectively."

Answered by AI

Is this medical study currently enrolling participants?

"The information hosted on clinicaltrials.gov suggests that this trial is not presently recruiting candidates, having been first posted on April 1st 2023 and most recently updated November 7th 2022. Nevertheless, there remain 549 other studies actively seeking patients right now."

Answered by AI

What is the ultimate goal of this clinical venture?

"The primary aim of this clinical trial, observed at Baseline, 1 month post intervention and 3 months post intervention is to measure the Change in Quality of Life Scale in Alzheimer's disease score from baseline. Assessing secondary outcomes include Change in Pearlin Mastery, Loss, and Competence Scale score from baseline gauging how much control an individual has over their life chances; Change in Caregiver Activity Survey score from baseline which measures time spent by caregivers assisting individuals with AD on a daily basis; as well as Change in Caregiver Assessment of Behavioral Skill Scale score from baseline evaluating caregiving skills based off a 17-item self-report"

Answered by AI

What type of participants are best suited to join in this clinical experiment?

"This trial is searching for 60 participants aged between forty and sixty-five who have been diagnosed with Alzheimer's disease. Besides these criteria, potential patients must also be able to read and write in either English, Mandarin Chinese or Korean; self-identify as Asian American women of a Chinese or Korean background; provide four hours of unpaid caregiving assistance on average each day to someone living within the community that does not currently plan on being institutionalized within six months; access the Internet through computers or mobile devices; and reside in America itself. It should also be noted that caregivers do not necessarily need to live with their recipients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Technology-based Information and Coaching Program Tailored for Asian American Midlife Women Who Are Family Caregivers of Persons With Alzheimer's Disease

Eun-Ok Im 2024. "Technology-based Information and Coaching Program Tailored for Asian American Midlife Women Who Are Family Caregivers of Persons With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05615233.